PsiOxus Therapeutics named EuropaBio’s Most Innovative European Biotech SME

Mercia EIS Funds | 3rd October, 2013
PsiOxus Therapeutics named EuropaBio’s Most Innovative European Biotech SME
Mercia EIS Funds | 1st October, 2013
World First: The Native Antigen Company succeeds in manufacturing all four DENV NS1 serotypes from human cell lines
Mercia EIS Funds | 30th September, 2013
Mercia Fund Management makes first digital sector investment with Metric
Mercia EIS Funds | 18th September, 2013
Mercia Fund Management announces Mike Hayes as head of new digital division
Mercia EIS Funds | 21st August, 2013
Smart Antenna Technologies brings single antenna solution to cellular handsets
Mercia EIS Funds | 31st July, 2013
Antitope Announces Research Agreement with ChemomAb for Generation of Composite Human Antibodies against Inflammatory Diseases
Mercia EIS Funds | 29th July, 2013
Mercia Fund Management makes investment to help accelerate the growth of PolyTherics
Mercia EIS Funds | 24th July, 2013
Oxford Genetics secures funding for DNA cloning system
Mercia EIS Funds | 26th June, 2013
How Mercia Fund Management funds University of Keele spin-outs
Mercia EIS Funds | 24th June, 2013
PsiOxus Therapeutics initiates second clinical study of oncolytic vaccine